Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix

Exclusion Criteria

• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period
• •Receipt of systemic glucocorticoids within 30 days of study enrollment
• •Administration of immunosuppressant, cytotoxic, or other immune-modifying drugs (other than glucocorticoids) or irradiation within 6 months prior to study enrollment or planned administration during the study period
• •Administration of immunoglobulins and/or blood products within 3 months prior to study enrollment or planned administration during the study period
• •Previous vaccination against influenza (2007-2008 influenza season)
• •History of anaphylactic or other allergic reaction to influenza vaccine, any other vaccine, or any vaccine component or excipient
• •History of Guillain-Barre Syndrome (GBS)
• •Acute disease, febrile illness, or upper respiratory infection at screening.
• •History of splenectomy
• •Any confirmed or suspected, acquired, congenital, or hereditary immunodeficiency or immunosuppressive condition (including human immunodeficiency virus \[HIV\]) based on medical history and physical examination
• •Acquired or congenital coagulation disorders or known thrombocytopenia
• •Current treatment with warfarin or heparin derivatives
• •Known use of an analgesic or antipyretic medication within 12 hours prior to treatment for the purposes of prophylaxis of adverse events
• •Any medical condition for which the US Advisory Committee on Immunization Practices recommends vaccination against influenza